trending Market Intelligence /marketintelligence/en/news-insights/trending/zNXGHNpOm9bp2w7cXhTQew2 content esgSubNav
In This List

Dova gets US FDA priority review of low blood platelet count treatment

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Dova gets US FDA priority review of low blood platelet count treatment

The U.S. Food and Drug Administration granted priority review to Dova Pharmaceuticals Inc.'s avatrombopag to treat thrombocytopenia in patients with chronic liver disease who are scheduled to undergo a procedure.

Thrombocytopenia is a condition that causes the blood platelet count to be lower than normal.

The application is based on two phase 3 trials in which the drug met all primary and secondary endpoints with high statistical significance.

The agency is expected to make a decision on the drug by May 21, 2018.